Advances of combined immunotherapy in tumor

ZHANG Rui; JIANG Tao; ZENG Tianzhu; YAO Wenbing; GAO Xiangdong; TIAN Hong

doi:10.11665/j.issn.1000-5048.20180401

Journal of China Pharmaceutical University > 2018 > 49(4): 383-391. > DOI: 10.11665/j.issn.1000-5048.20180401

ZHANG Rui, JIANG Tao, ZENG Tianzhu, YAO Wenbing, GAO Xiangdong, TIAN Hong. Advances of combined immunotherapy in tumor[J]. Journal of China Pharmaceutical University, 2018, 49(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20180401

Citation:

PDF (2211 KB)

Advances of combined immunotherapy in tumor

More Information

Graphical Abstract

Abstract

Abstract

Immune checkpoints are inhibitory signaling pathways in the immune system that maintain balance with co-stimulatory molecules, maintain tolerance to their own tissues, and avoid autoimmune responses. The development of tumors is accompanied by the upregulation of co-suppressor molecules and related ligands, causing the decline or exhaustion of T cell functions, which makes tumor cells excape immune surveillance. The development of monoclonal antibodies against inhibitory receptors and ligands to regulate T cell activity and improve antitumor immune responses have achieved promising clininal results. Combined treatment of immunomodulatory signaling pathways also showed a certain of synergy. This article summarizes the evaluation of combined tumor immunotherapy strategies and synergies, and outlooks the feasibility of combined immunotherapy and the selection of immunization strategies.
- immunotherapy,
- immune checkpoints,
- combined treatment,
- synergy

FullText(HTML)

References (54)

References

[1]	Van Elsas A,Hurwitz AA,Allison JP.Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4(CTLA-4)and granulocyte/macrophage colony-stimulating factor(GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation[J].J Exp Med,1999,190(3):355-366.
[2]	Quezada SA,Peggs KS,Curran MA,et al.CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells[J].J Clin Invest,2006,116(7):1935-1945.
[3]	Fu J,Malm IJ,Kadayakkara DK,et al.Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors[J].Cancer Res,2016,74(15):4042-4052.
[4]	Sakkuishi K,Apetoh L,Sullivan JM,et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity[J].J Exp Med,2010,207(10):2187-2194.
[5]	Duraiswamy J,Freeman GJ,Coukos G.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors-response[J].Cancer Res,2014,74(2):633-634.
[6]	Postow MA,Chesney J,Pavlick AC,et al.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J].N Engl J Med,2015,372(21):2006-2017.
[7]	Luheshi NM,Coates-Ularichsen J,Harper J,et al.Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model[J].Oncotarget,2016,7(14):18508-18520.
[8]	Chen S,Lee LF,Fisher TS,et al.Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model[J].Cancer Immunol Res,2015,3(2):149-160.
[9]	Mace TA,Shakya R,Pitarresi JR,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
[10]	Ma YF,Chen C,Li D,et al.Targeting of interleukin(IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer[J].Oncotarget,2017,8(5):7614-7624.
[11]	Ebert PR,Cheung J,Yang Y,et al.MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade[J].Immunity,2016,44(3):609-621.
[12]	Liu Y,Cai P,Wang N,et al.Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma[J].Biochem Biophys Res Commun,2017,484(2):378-384.
[13]	Vermeij R,Leffers N,Hoogeboom B N,et al.Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer:a single-arm phase II study[J].Int J Cancer,2012,131(5):670-680.
[14]	Beatty GL,Chiorean EG,Fishman MP,et al.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J].Science,2011,331(6024):1612-1616.
[15]	Sluis TCVD,Duikeren SV,Huppelschoten S,et al.Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death[J].Clin Cancer Res,2015,21(4):781-794.
[16]	Patel SP,Kurzrock R.PD-L1 expression as a predictive biomarker in cancer immunotherapy[J].Mol Cancer Ther,2015,14(4):847-856.
[17]	Boland JM,Kwon ED,Harrington SM,et al.Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung[J].Clin Lung Cancer,2013,14(2):157-163.
[18]	Amarnath S,Mangus CW,Wang JC,et al.The PDL1-PD1 axis converts human TH1 cells into regulatory T cells[J].Sci Transl Med,2011,3(111):111-120.
[19]	Xia Y,Jeffrey Medeiros L,Young KH.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies[J].Biochim Biophys Acta,2016,1865(1):58-71.
[20]	Powlets T,Eder JP,Fine GD,et al.MPDL3280A(anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature,2014,515(7528):558-562.
[21]	Ledford H.Promising cancer drugs may speed tumours in some patients[J].Nature,2017,544(7648):13-14.
[22]	Bharat A,Fields RC,TRULOCK E P,et al.Induction of IL-10 suppressors in lung transplant patients by CD4⁺25⁺ regulatory T cells through CTLA-4 signaling[J].J Immunol,2006,177(8):5631-5638.
[23]	Qureshhi OS,Zheng Y,Nakamura K,et al.Trans-endocytosis of CD80 and CD86:a molecular basis for the cell-extrinsic function of CTLA-4[J].Science,2011,332(6029):600-603.
[24]	Reck M,Bondarenko I,Luft A,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer:results from a randomized,double-blind,multicenter phase 2 trial[J].Ann Oncol,2013,24(1):75-83.
[25]	Monney L,Sabatos CA,Gaglia JL,et al.Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J].Nature,2002,415(6871):536-541.
[26]	Anaerson AC.Tim-3:an emerging target in the cancer immunotherapy landscape[J].Cancer Immunol Res,2014,2(5):393-398.
[27]	Sakuishi K,Apetoh L,Sullivan JM,et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity[J].J Exp Med,2010,207(10):2187-2194.
[28]	Fourcade J,Sun ZM,Guillaume P,et al.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8⁺ T cell dysfunction in melanoma patients[J].J Exp Med,2010,207(10):2175-2186.
[29]	Zhang B,Wu T,Chen M,et al.The CD40/CD40L system:a new therapeutic target for disease[J].Immunol Lett,2013,153(1/2):58-61.
[30]	Nowak AK,Cook AM,Mcdonnell AM,et al.A phase 1b clinical trial of the CD40 activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma[J].Ann Oncol,2015,26(12):2483-2490.
[31]	Hintzen RQ,Lens SM,Lammers K,et al.Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation[J].J Immunol,1995,154(6):2612-2623.
[32]	Borst J,Hendriks J,Xiao Y.CD27 and CD70 in T cell and B cell activation[J].Curr Opin Immunol,2005,17(3):275-281.
[33]	Burris HA,Infante JR,Ansell SM,et al.Safety and activity of varlilumab,a novel and first-in-class agonist anti-CD27 antibody,in patients with advanced solid tumors[J].J Clin oncol,2017,35(18):2028-2036.
[34]	Hu X,Li B,Li X,et al.Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2[J].J Immunol,2014,192(3):1320-1331.
[35]	Naga M,Jacobhirsch J,Vernitsky H,et al.TNF activates a NF-kappaB-regulated cellular program in human CD45RA-regulatory T cells that modulates their suppressive function[J].J Immunol,2010,184(7):3570-3581.
[36]	Sandercock AM,Rust S,Guillard S,et al.Identification of anti-tumour biologics using primary tumour models,3-D phenotypic screening and image-based multi-parametric profiling[J].Mol Cancer,2015,14(1):147-150.
[37]	Rosenberg SA,Yang JC,Restifo NP.Cancer immunotherapy:moving beyond current vaccines[J].Nat Med,2004,10(9):909-915.
[38]	Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells:can anything replace a dendritic cell[J]?Nat Rev Immunol,2014,14(11):719-730.
[39]	Ott PA,Hodi FS,Kaufman HL,et al.Combination immunotherapy:a road map[J].J Immunother of Cancer,2017,5(1):16-18.
[40]	Li G,Lu C,Gao J,et al.Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage[J].Int J Clin Exp Pathol,2015,8(6):6512-6518.
[41]	Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J].J Immunother,2015,38(1):1-11.
[42]	Sierro SR,Donda A,Perret R,et al.Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity[J].Eur J Immunol,2011,41(8):2217-2228.
[43]	Li Z,Li N,Li F,et al.Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma[J].Medicine,2016,95(52):5749-5751.
[44]	Ye Q,Song DG,Poussin M,et al.CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor[J].Clin Cancer Res,2014,20(1):44-55.
[45]	Corcoran RB,Contino G,Deshpande V,et al.STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis[J].Cancer Res,2011,71(14):5020-5024.
[46]	Farren MR,Mace TA,Geyer S,et al.Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer[J].Clin cancer Res,2016,22(10):2565-2574.
[47]	Tada S, Iida M, Matsui T, et al. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice[J].PLoS One,2013,8(1):531-535.
[48]	Simard FA,Cloutier A,Ear T,et al.MEK-independent ERK activation in human neutrophils and its impact on functional responses[J].J Leukoc Biol,2015,98(4):565-573.
[49]	Zitvogel L,Galluzzi L,Smyth MJ,et al.Mechanism of action of conventional and targeted anticancer therapies:reinstating immunosurveillance[J].Immunity,2013,39(1):74-88.
[50]	Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation,cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells[J].J Immunol,2003,170(10):4905-4913.
[51]	Peng S,Lyford-Pike S,Akpeng B,et al.Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine[J].Cancer Immunol,2013,62(1):171-182.
[52]	Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival[J].Nat Med,2012,18(8):1254-1261.
[53]	Kang TH,Mao CP,Lee SY,et al.Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity[J].Cancer Res,2013,73(8):2493-2504.
[54]	Melero I,Berman DM,Aznar MA,et al.Evolving synergistic combinations of targeted immunotherapies to combat cancer[J].Nat Rev Cancer,2015,15(8):457-472.

[1]	MO Xinhe, WAN Youqiong, WANG Sibu, MA Qin, ZHANG Jun, CHEN Ying. Ameliorative effect of baicalin nanomedicine on hydrogen peroxide-induced senescence of human umbilical vein vascular endothelial cells[J]. Journal of China Pharmaceutical University, 2025, 56(1): 110-118. DOI: 10.11665/j.issn.1000-5048.2024052101
[2]	WANG Dandan, KORAMAGAZI Arouna, MAO Yong, YU Feng. Rhein induces apoptosis in L-02 cells via reactive oxygen species-independent endoplasmic reticulum stress pathway[J]. Journal of China Pharmaceutical University, 2016, 47(2): 215-221. DOI: 10.11665/j.issn.1000-5048.20160215
[3]	SHEN Kai, KOU Junping, YU Boyang. Research advances in the mechanisms of active components in Chinese materia medica against oxidative stress-induced neuronal apoptosis[J]. Journal of China Pharmaceutical University, 2015, 46(5): 532-540. DOI: 10.11665/j.issn.1000-5048.20150503
[4]	WANG Li, LI Mingdan, LU Yi, ZHANG Chaofeng, XU Xianghong, ZHANG Mian. Mechanism of apoptosis induced by peptide-rich fraction from the root of Aster tataricus in liver L-02 cells[J]. Journal of China Pharmaceutical University, 2014, 45(4): 469-474. DOI: 10.11665/j.issn.1000-5048.20140415
[5]	QI Cuiling, ZHOU Xinlei, YE Jie, YANG Yang, ZHANG Qianqian, LI Jiangchao, WANG Lijing. Andrographolide induces Tb cell apoptosis by activating Caspase-3/PARP[J]. Journal of China Pharmaceutical University, 2013, 44(6): 559-562. DOI: 10.11665/j.issn.1000-5048.20130614
[6]	LIU Zhi-yong, NIU Zhi-yuan, ZHENG Wei, SHEN Ping-ping. Effects of p-ERK1/2 on nitric oxide donor induced apoptosis of HepG2 cells[J]. Journal of China Pharmaceutical University, 2012, 43(6): 530-534.
[7]	Inhibition of Hydrogen Peroxide-induced PC12 Cell Apoptosis by Modafinil[J]. Journal of China Pharmaceutical University, 2004, (3): 77-81.
[8]	Protective Effects of MCl-186 on Apoptosis in PC12 Cells Induced by H2O2[J]. Journal of China Pharmaceutical University, 2004, (1): 62-66.
[9]	Effects of Crocetin on the Myocardial Cell Damages Due to Oxidative Stress[J]. Journal of China Pharmaceutical University, 2003, (5): 66-69.
[10]	Inhibition of Puerarin on the H_2O_2-induced Apoptosis of Smooth Muscle Cells[J]. Journal of China Pharmaceutical University, 2002, (3): 75-78.

Cited By

Get Citation

PDF

XML

Article views PDF downloads

Turn off MathJax

Article Contents

Abstract

References

Advances of combined immunotherapy in tumor

Abstract

References

Related Articles

Catalog

Advances of combined immunotherapy in tumor

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content